Skip to main content

Dravet Syndrome clinical trials at UCSF

7 in progress, 3 open to eligible people

Showing trials for
  • Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

    open to eligible people ages 2-56

    The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in children and adults with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS). Participants will receive their standard anti-seizure therapy, plus tablets of soticlestat. There will be scheduled visits and follow-up phone calls throughout the study.

    San Francisco, California and other locations

  • EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome

    open to eligible people ages 2 years and up

    The purpose of this study is to evaluate the safety and efficacy of EPX-100 as adjunctive therapy in children and adult participants with Dravet Syndrome.

    San Francisco, California and other locations

  • LP352 in Subjects With Developmental and Epileptic Encephalopathy

    open to eligible people ages 12-65

    The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.

    San Francisco, California and other locations

  • ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

    Sorry, not yet accepting patients

    ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to <36 months. Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study.

    San Francisco, California and other locations

  • Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

    Sorry, in progress, not accepting new patients

    The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS. Participants will receive their standard antiseizure therapy, plus either a tablet of soticlestat or placebo for 16 weeks. A placebo looks just like soticlestat but will not have any medicine in it. Participants may continue treatment in an extension study, based on the extension study's entry criteria. Those that want to stop treatment will have a gradual dose reduction during 1 week and then be followed up for 2 weeks.

    San Francisco, California and other locations

  • STK-001 for Patients With Dravet Syndrome

    Sorry, accepting new patients by invitation only

    Stoke Therapeutics is evaluating the long-term safety & tolerability of repeated doses of STK-001 in patients with Dravet syndrome who previously participated in studies of STK-001. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

    San Francisco, California and other locations

  • Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

    Sorry, in progress, not accepting new patients

    Stoke Therapeutics is evaluating the safety and tolerability of single and multiple ascending doses of STK-001 in patients with Dravet syndrome. Change in seizure frequency, overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

    San Francisco, California and other locations

Our lead scientists for Dravet Syndrome research studies include .

Last updated: